The major aim of this research study is to investigate the relationship between genetic variation in DNA (inherited code material in the cells of the body) and factors affecting transplant outcomes, like the drugs people receive or the way their immune systems work, for example. To do this, investigators will collect blood samples from participants. Genetic material will be separated from each blood sample and analyzed, looking for genetic variation.
In the past, the major problems in kidney transplantation were surgical complications, acute rejection, and infections. Right now, researchers are focusing on improving immune suppression therapy and achieving better long-term survival of kidney transplants. One of the ways to try to understand what causes loss of function after many years is to find out if there is a genetic factor involved. There are a number of differences in specific genes that have been identified and are thought to affect transplant outcomes. Studying these gene variations (differences between people or differences between populations) is important in determining whether these variations are related to transplant outcomes and how this information can help patients achieve better long-term transplant survival.
Study Type
OBSERVATIONAL
Enrollment
1,552
University of Alabama
Birmingham, Alabama, United States
University of Minnesota
Minneapolis, Minnesota, United States
Hennepin County Medical Center
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Transplant recipient genotypes: time to chronic graft disfunction
Time frame: Day 0 to Year 5
Transplant recipient genotypes: time to a persistent 25% decrease in Estimated Glomerular Filtration Rate (eGFR)
eGFR: Estimated GFR test results are a measure of kidney function.
Time frame: Day 0 to Year 5
Transplant recipient genotypes: time to acute rejection
Time frame: Day 0 to Year 5
Transplant recipient genotypes: time to allograft failure
allograft failure is defined as graft loss or participant death.
Time frame: Day 0 to Year 5
Donor Genotypes: time to chronic graft dysfunction
The time to dysfunction of the donated organ.
Time frame: Day 0 to Year 5
Donor Genotypes: time to a persistent 25% decrease in eGFR
The time to a persistent 25% decrease in eGFR in the donated organ's recipient.
Time frame: Day 0 to year 5
Donor Genotypes: time to allograft failure
The time to the failure of the donated organ (defined as graft loss or participant death).
Time frame: Day 0 to Year 5
Recipient genotypes: time to select mycophenolate-related toxicities (leukopenia, anemia)
Time frame: Day 0 to Year 5
Recipient genotypes: time to select Calcineurin Inhibitor (CNI)-related toxicities
Toxicities may include: new onset diabetes or nephrotoxicity. CNI: calcineurin inhibitor
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Alberta
Edmonton, Alberta, Canada
Time frame: Day 0 to Year 5
Recipient genotypes: repeated measures of clinically obtained tacrolimus trough blood levels
Time frame: Day 0 to Year 5
Recipient candidate genotypes: Calcineurin (CN) and IMPDH protein activity and expression
CN: Calcineurin. IMPDH: Inosine-5'-monophosphate dehydrogenase
Time frame: Day 0 to Year 5
Time to composite endpoint of graft loss or death or persistent 25% increase in serum creatinine
Time frame: Day 0 to Year 5
Time to renal biopsy with presence of the following semi-quantitative pathology endpoints: patterns of Banff biopsy score, presence of circulating anti-donor anti-Human Leukocyte Antigen (HLA) antibodies, C4d positivity
Time frame: Day 0 to Year 5
Slope of eGFR
Time frame: Day 0 to Year 5
Delayed graft function
Time frame: Day 0 to Year 5
Time to Epstein-Barr virus (EBV) and Cytomegalovirus (CMV) infection
EBV: Epstein-Barr virus. CMV: cytomegalovirus.
Time frame: Day 0 to Year 5